PL3769753T3 - Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu - Google Patents

Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu

Info

Publication number
PL3769753T3
PL3769753T3 PL20186965T PL20186965T PL3769753T3 PL 3769753 T3 PL3769753 T3 PL 3769753T3 PL 20186965 T PL20186965 T PL 20186965T PL 20186965 T PL20186965 T PL 20186965T PL 3769753 T3 PL3769753 T3 PL 3769753T3
Authority
PL
Poland
Prior art keywords
preparation
fluticasone propionate
ophthalmic aqueous
sterile ophthalmic
propionate form
Prior art date
Application number
PL20186965T
Other languages
English (en)
Inventor
Jean-Michel BUKOWSKI
Akshay NADKARNI
José L. BOYER
Brigitte DUQUESROIX-CHAKROUN
Tomas Navratil
Original Assignee
Nicox Ophthalmics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics, Inc. filed Critical Nicox Ophthalmics, Inc.
Publication of PL3769753T3 publication Critical patent/PL3769753T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL20186965T 2019-07-23 2020-07-21 Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu PL3769753T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US201962942551P 2019-12-02 2019-12-02
EP20186965.8A EP3769753B1 (en) 2019-07-23 2020-07-21 Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Publications (1)

Publication Number Publication Date
PL3769753T3 true PL3769753T3 (pl) 2022-04-04

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20186965T PL3769753T3 (pl) 2019-07-23 2020-07-21 Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu

Country Status (23)

Country Link
US (3) US20220241296A1 (pl)
EP (1) EP3769753B1 (pl)
JP (2) JP7021301B2 (pl)
KR (1) KR20220038443A (pl)
CN (2) CN111821261B (pl)
AU (1) AU2020317084A1 (pl)
CA (1) CA3145055A1 (pl)
CY (1) CY1124930T1 (pl)
DK (1) DK3769753T3 (pl)
ES (1) ES2905793T3 (pl)
HR (1) HRP20220165T1 (pl)
HU (1) HUE057416T2 (pl)
LT (1) LT3769753T (pl)
MD (1) MD3769753T2 (pl)
MX (1) MX420447B (pl)
PH (1) PH12022550003A1 (pl)
PL (1) PL3769753T3 (pl)
PT (1) PT3769753T (pl)
RS (1) RS62932B1 (pl)
SI (1) SI3769753T1 (pl)
SM (1) SMT202200082T1 (pl)
TW (1) TWI864053B (pl)
WO (1) WO2021014348A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220165T1 (hr) * 2019-07-23 2022-04-29 Nicox Ophthalmics, Inc. Postupak priprave sterilnih oftalmoloških vodenih suspenzija nanokristala flurikazona-propionata oblika a
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300936T1 (de) * 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
MX2011013061A (es) * 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas de fluticasona y metodos de uso.
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
EP2847207B1 (en) * 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
RU2652352C2 (ru) * 2012-12-17 2018-04-25 Глаксо Груп Лимитед Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑
HRP20220165T1 (hr) * 2019-07-23 2022-04-29 Nicox Ophthalmics, Inc. Postupak priprave sterilnih oftalmoloških vodenih suspenzija nanokristala flurikazona-propionata oblika a

Also Published As

Publication number Publication date
MX2022000928A (es) 2022-02-22
SI3769753T1 (sl) 2022-04-29
US20220241296A1 (en) 2022-08-04
HUE057416T2 (hu) 2022-05-28
MX420447B (es) 2025-02-10
PT3769753T (pt) 2022-02-15
KR20220038443A (ko) 2022-03-28
US11406596B2 (en) 2022-08-09
US20210023001A1 (en) 2021-01-28
JP2022062172A (ja) 2022-04-19
US20220323352A1 (en) 2022-10-13
CN111821261B (zh) 2022-07-26
TW202116326A (zh) 2021-05-01
AU2020317084A1 (en) 2022-03-03
HRP20220165T1 (hr) 2022-04-29
JP2021017449A (ja) 2021-02-15
CN115120557A (zh) 2022-09-30
CA3145055A1 (en) 2021-01-28
CN115120557B (zh) 2024-05-07
PH12022550003A1 (en) 2022-11-14
CY1124930T1 (el) 2023-01-05
ES2905793T3 (es) 2022-04-12
DK3769753T3 (da) 2022-01-31
TWI864053B (zh) 2024-12-01
WO2021014348A1 (en) 2021-01-28
SMT202200082T1 (it) 2022-03-21
JP7494230B2 (ja) 2024-06-03
EP3769753B1 (en) 2021-11-17
CN111821261A (zh) 2020-10-27
LT3769753T (lt) 2022-05-10
MD3769753T2 (ro) 2022-04-30
EP3769753A1 (en) 2021-01-27
RS62932B1 (sr) 2022-03-31
JP7021301B2 (ja) 2022-02-16

Similar Documents

Publication Publication Date Title
SI3769753T1 (sl) Postopek za pripravo sterilnih oftalmičnih vodnih nanokristalnih suspenzij flutikazon propionata oblike A
ES3064674T3 (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
EP3544666A4 (en) BODY LIGHT DEVIATION SYSTEM AND METHOD
GB2582265B (en) A method for adjusting the suspension of a vehicle
SG11202109296WA (en) Pellicle intermediary body, pellicle, method for manufacturing of pellicle intermediary body, and pellicle manufacturing method
EP3870637A4 (en) NANOCELLULOSE HYDROPHOBIC MODIFICATION PROCESS DURING MANUFACTURING
IL286589A (en) A compound for isolating unwanted antibodies in a patient
IL289520A (en) A method for stabilizing the degree of acidity of a water-based medicinal preparation
HUP1900315A1 (hu) Ipari eljárás nagytisztaságú ösztetrol hatóanyag elõállítására
CA3300764A1 (en) A nasal seal for a respiratory patient interface
HUE072769T2 (hu) Gyártósor szemészeti lencsék elõállításához
HUE073418T2 (hu) Gyártósor szemészeti lencsék elõállításához
HUE073394T2 (hu) Gyártósor szemészeti lencsék elõállítására
HUE072768T2 (hu) Gyártósor szemészeti lencsék elõállítására
EP4076468A4 (en) FILTER AID FOR NON-AQUEOUS LIQUIDS
SG11202000561YA (en) Modular production line for the production of ophthalmic lenses
HUE067878T2 (hu) Eljárás alkilamidotiazolok gyártásához
MA53146A (fr) Procédé de préparation de suspensions nanocristallines de propionate de fluticasone aqueux ophtalmique stérile
HUE073341T2 (hu) Gyártósor oftalmikus lencsék elõállítására
LT4436662T (lt) Naftiridinono dariniai ligos ar sutrikimo gydymui
HUE055078T2 (hu) Eljárás cellulóz-karbamát elõállítására
Khare et al. A new method for removal of eyelid margin molluscum
ZA202104921B (en) Method for the manufacturing of chitin derivatives through treatment with ultrasounds
PL4021505T3 (pl) Lek do leczenia chorób zakaźnych
PL3725774T3 (pl) Sposób wytwarzania środka farmaceutycznego